Fusion Pharmaceuticals Stock Forecast, Price & News

Fusion Pharmaceuticals (NASDAQ:FUSN) Frequently Asked Questions

Is Fusion Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fusion Pharmaceuticals stock.
View analyst ratings for Fusion Pharmaceuticals or view top-rated stocks.

When is Fusion Pharmaceuticals' next earnings date?

Fusion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Fusion Pharmaceuticals.

How were Fusion Pharmaceuticals' earnings last quarter?

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.58) by $0.13. The company earned $0.33 million during the quarter.
View Fusion Pharmaceuticals' earnings history.

What price target have analysts set for FUSN?

4 Wall Street analysts have issued 1 year price objectives for Fusion Pharmaceuticals' stock. Their forecasts range from $17.00 to $19.00. On average, they anticipate Fusion Pharmaceuticals' stock price to reach $18.00 in the next year. This suggests a possible upside of 210.3% from the stock's current price.
View analysts' price targets for Fusion Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Fusion Pharmaceuticals' key executives?

Fusion Pharmaceuticals' management team includes the following people:

• Dr. John F. Valliant, Founder, CEO & Director (Age 51, Pay $845.5k)
• Mr. John J. Crowley CPA, Chief Financial Officer (Age 47, Pay $646.43k)
• Dr. Eric Burak, Chief Scientific Officer (Age 56, Pay $600.78k)
• Dr. James J. O'Leary, Chief Medical Officer (Age 56, Pay $537.64k)
• Ms. Lynn Wick, Exec. Director of Fin. & Operations
• Ms. Amanda Cray, Sr. Director of Investor Relations & Corp. Communications
• Ms. Maria D. Stahl, Chief Legal Officer (Age 50)
• Dr. Marc Schwabish Ph.D., SVP of Bus. Devel. and US Operations
• Dr. Isabelle Dussault Ph.D., Sr. VP of Research

Who are some of Fusion Pharmaceuticals' key competitors?

Some companies that are related to Fusion Pharmaceuticals include Century Therapeutics (IPSC), Vaxart (VXRT), Scholar Rock (SRRK), Immunovant (IMVT), Icosavax (ICVX), BioAtla (BCAB), Omega Therapeutics (OMGA), SOPHiA Genetics (SOPH), Tenaya Therapeutics (TNYA), Agenus (AGEN), Gritstone bio (GRTS), Monte Rosa Therapeutics (GLUE), Finch Therapeutics Group (FNCH), Sutro Biopharma (STRO) and MeiraGTx (MGTX).
View all of FUSN's competitors.

What other stocks do shareholders of Fusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK).

When did Fusion Pharmaceuticals IPO?

(FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Fusion Pharmaceuticals' stock symbol?

Fusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "FUSN."

Who are Fusion Pharmaceuticals' major shareholders?

Fusion Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Johnson & Johnson (8.52%), Point72 Asset Management L.P. (1.99%), BlackRock Inc. (0.96%), Victory Capital Management Inc. (0.62%), Morgan Stanley (0.19%) and Sectoral Asset Management Inc (0.09%). Company insiders that own Fusion Pharmaceuticals stock include Adams Street Partners Llc, Johnson & Johnson and Steven Gannon.
View institutional ownership trends for Fusion Pharmaceuticals.

Which major investors are selling Fusion Pharmaceuticals stock?

FUSN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., and Victory Capital Management Inc..
View insider buying and selling activity for Fusion Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Fusion Pharmaceuticals stock?

FUSN stock was bought by a variety of institutional investors in the last quarter, including Johnson & Johnson, Sectoral Asset Management Inc, Millennium Management LLC, Morgan Stanley, Geode Capital Management LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Fusion Pharmaceuticals stock in the last two years include Johnson & Johnson, and Steven Gannon.
View insider buying and selling activity for Fusion Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Fusion Pharmaceuticals?

Shares of FUSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fusion Pharmaceuticals' stock price today?

One share of FUSN stock can currently be purchased for approximately $5.80.

How much money does Fusion Pharmaceuticals make?

Fusion Pharmaceuticals has a market capitalization of $249.78 million. The company earns $-78.33 million in net income (profit) each year or ($1.82) on an earnings per share basis.

How many employees does Fusion Pharmaceuticals have?

Fusion Pharmaceuticals employs 61 workers across the globe.

What is Fusion Pharmaceuticals' official website?

The official website for Fusion Pharmaceuticals is fusionpharma.com.

Where are Fusion Pharmaceuticals' headquarters?

Fusion Pharmaceuticals is headquartered at 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6.

How can I contact Fusion Pharmaceuticals?

Fusion Pharmaceuticals' mailing address is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. The company can be reached via phone at 289-799-0891 or via email at [email protected].